Last update: Feb. 12, 2019


Low Risk for breastfeeding

Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

A tertiary antimuscarinic amine with actions similar to atropine. Indicated as a urinary antispasmodic in bladder incontinence problems.
Oral administration 1 to 3 times a day.

Since the last update we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data - large volume of distribution and high percentage of protein binding (AEMPS2016, Ortho2008) - make it unlikely that significant quantities will be transferred to breastmilk.

Its very low oral bioavailability (AEMPS2016, Ortho2008, Duchamos 1988) hinders transfer to infant plasma from breastmilk, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.

Milk production should be monitored, since anticholinergics can reduce milk production.

Possible anticholinergic symptoms (dry mouth, constipation...) in the infant should be monitored.

Expert authors consider the use of this medication to probably be safe during breastfeeding (Brigs 2017, Hale 2017 p 737).
Other similar anticholinergics, such as atropine, are considered by the American Academy of Pediatrics to usually be compatible with breastfeeding.

See below the information of this related product:


Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

オキシブチニン is Oxybutynin in Japanese.

Is written in other languages:

オキシブチニン is also known as


オキシブチニン belongs to this group or family:


Main tradenames from several countries containing オキシブチニン in its composition:


Variable Value Unit
Oral Bioavail. 6 (2 - 11) %
Molecular weight 358 daltons
Protein Binding 91 - 93 %
VD 2,76 l/Kg
pKa 8,77 -
Tmax 1 hours
T1/2 2 - 4 hours


  1. Hale TW, Rowe HE. Medications & Mothers' Milk. A Manual of Lactation Pharmacology. Springer Publishing Company. 2017
  2. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. 11th edition (acces on line) 2017
  3. AEMPS-Sanofi. Oxibutinina. Ficha técnica. 2016 Full text (in our servers)
  4. Ortho. Oxybutynin. Drug Summary. 2008 Full text (in our servers)
  5. Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1988 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by La Liga de la Leche de México from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM